Search

Your search keyword '"Gupta, Rachna"' showing total 357 results
Start Over Author "Gupta, Rachna"
357 results on '"Gupta, Rachna"'

7. Contributors

Author

Abdelhamid, Hani Nasser, primary, Ahmad, Khursheed, additional, Almessiere, M.A., additional, Analisa, S., additional, Araujo, Robson Teixeira, additional, Ashok Kumar, S., additional, Asiri, Abdullah M., additional, Atacan, Keziban, additional, Baykal, A., additional, Bhatia, Amarpreet K., additional, Bhushan, Mayank, additional, Boddula, Rajender, additional, Bucio, Emilio, additional, Camacho-Cruz, Luis A., additional, Carabineiro, Sónia A.C., additional, Cedillo-Valverde, Gerardo, additional, Chavda, Nitya, additional, Chokkareddy, Rajasekhar, additional, Cruz-Gómez, Angélica, additional, Daphne, V., additional, Dewangan, Shippi, additional, Dinesh, A., additional, Durka, M., additional, Gaddam, Sashivinay Kumar, additional, Güy, Nuray, additional, Gupta, Vikas, additional, Gupta, Rachna, additional, Hashemi-Moghaddam, Hamid, additional, Inbanathan, S.S.R., additional, Jaganathan, S.K., additional, Jain, Ankit, additional, Jarvin, M., additional, Julie, M. Maria, additional, Kabane, Bakusele, additional, Kanchi, Suvardhan, additional, Kanmani Raja, K., additional, Katari, Naresh Kumar, additional, Keerthana, C., additional, Kesharwani, Payal, additional, Khan, Anish, additional, Kilele, Joan Chepkoech, additional, Kim, Haekyoung, additional, Kumar, K. Elaya, additional, Kumar, Amit, additional, Kumar, R. Thilak, additional, Kumari, Mahima, additional, Laishram, Robindro Singh, additional, Machado, Fabricio, additional, Malik, Parth, additional, Malik, Maqsood Ahmad, additional, Manikandan, Ayyar, additional, Muthulingam, S., additional, Neto, Weslany Silvério, additional, Nivetha, P., additional, Prajapati, Shiv Kumar, additional, Rajikha, R., additional, Ramyakrishna, Pothu, additional, Ratna Monica, J. Helen, additional, Redhi, Gan G., additional, Resende, Graciane, additional, Rosaline, D. Rani, additional, Rubini, S. Hamsa, additional, Sampath, Shobana, additional, Sathana, V., additional, Sharma, Bhasha, additional, Sharma, Kanika, additional, Sharma, Swapnil, additional, Sheha, Reda R., additional, Shekhar, Shashank, additional, Shinde, Mahesh A., additional, Simões Dutra, Gabriel Victor, additional, Singh, Ajaya Kumar, additional, Slimani, Y., additional, Somya, Amita, additional, Srividya, G., additional, Susan, Md. Abu Bin Hasan, additional, Sykam, Kesavarao, additional, Thanrasu, K., additional, Topare, Niraj S., additional, Vasthi, S. Stephila, additional, and Velazco-Medel, Marlene A., additional

Published
2024
Full Text
View/download PDF

13. Toxicology in drug research

Author

Mishra, Ankit, primary, Mishra, Pranali, additional, Tekade, Muktika, additional, Gupta, Rachna, additional, Rajpoot, Kuldeep, additional, Mohamed, Farahidah, additional, and Tekade, Rakesh Kumar, additional

Published
2023
Full Text
View/download PDF

14. List of contributors

Author

Achanta, Nagendra Sai Kumar, primary, Al-Attraqchi, Omar Husham Ahmed, additional, Al-Shar'i, Nizar, additional, Anup, Neelima, additional, Arafat, Basel, additional, Bain, Anoothi, additional, Bansal, Kuldeep Kumar, additional, Behera, Santosh Kumar, additional, Chauhan, Nagendra Singh, additional, Chellappan, Dinesh Kumar, additional, Desai, Nimeet, additional, Deshpande, Mrudul, additional, Dhamne, Sneha A., additional, Dixit, Pankaj Vinodrao, additional, Gadeval, Anuradha, additional, Gandhi, Sanyam, additional, Gomte, Shyam, additional, Gondaliya, Piyush, additional, Gupta, Deepak Kumar, additional, Gupta, Rachna, additional, Gupta, Tanisha, additional, Ingole, Shweta, additional, Joshi, Megha, additional, Kalpeshkumar, Rana Dhwani, additional, Koppisetti, Hari Priya, additional, Kulkarni, Madhur, additional, Kumar, Manoj, additional, Lohar, Priyanka, additional, Maheshwari, Rahul, additional, Mansour, Randa SH., additional, Mhatre, Mahi, additional, Mishra, Ankit, additional, Mishra, Dinesh Kumar, additional, Mishra, Pranali, additional, Mohamed, Farahidah, additional, More, Anand, additional, Nalla, Lakshmi Vineela, additional, Panchal, Mamata, additional, Pardeshi, Krutika H., additional, Pawar, Bhakti, additional, Pawar, Vinayak, additional, Pingale, Prashant L., additional, Pingale, Anjali, additional, Polaka, Suryanarayana, additional, Raji, Sivarupa, additional, Rajpoot, Kuldeep, additional, Rajput, Amarjitsing P., additional, Raval, Nidhi, additional, Safavi, Maliheh, additional, Sarker, Satyajit D., additional, Saudagar, Neetu R., additional, Sayyed, Adil Ali, additional, Sengupta, Pinaki, additional, Shakya, Ashok K., additional, Sharma, Manish Kumar, additional, Sharma, Manish, additional, Sharma, Mukesh C., additional, Sheth, Anjani, additional, Shukla, Havish, additional, Sreeharsha, Nagaraja, additional, Tambe, Vishakha, additional, Teja, Paritala Sree, additional, Tekade, Muktika, additional, Tekade, Rakesh Kumar, additional, Tiwari, Akhilesh, additional, Vasdev, Nupur, additional, Wani, Sakshi P., additional, and Wankhede, Yogesh, additional

Published
2023
Full Text
View/download PDF

17. Cost and Care Insight: An Interactive and Scalable Hierarchical Learning System for Identifying Cost Saving Opportunities

Author

Zhang, Yuan, Koepke, David, Hao, Bibo, Mei, Jing, Min, Xu, Gupta, Rachna, Joshi, Rajashree, McNaughton, Fiona, Chen, Zhan-Heng, Zhao, Bo-Wei, Hu, Lun, Hu, Pengwei, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Huang, De-Shuang, editor, Jo, Kang-Hyun, editor, Jing, Junfeng, editor, Premaratne, Prashan, editor, Bevilacqua, Vitoantonio, editor, and Hussain, Abir, editor

Published
2022
Full Text
View/download PDF

20. Hydrocephalus associated with a molar tooth sign: A distinct subtype of Joubert syndrome.

Author

Gafner, Michal, Haddad, Leila, Gupta, Rachna, Leibovitz, Zvi, Zilberman Ron, Itamar, Ben‐Sira, Liat, Libzon, Stephanie, Gindes, Liat, Boltshauser, Eugen, and Lerman‐Sagie, Tally

Subjects
JOUBERT syndrome, HYDROCEPHALUS, THIRD trimester of pregnancy, SECOND trimester of pregnancy, MAGNETIC resonance imaging
Abstract

Hydrocephalus is rarely described in Joubert‐Boltshauser syndrome (JBTS). The aim of this study was to investigate whether this association is a chance occurrence or potentially signifies a new phenotypic subtype. The databases of Wolfson Medical Center, Sourasky Medical Center, and EB's personal collection were reviewed. Records from an additional family were obtained from RG. The patients' medical records, prenatal ultrasounds, and magnetic resonance imaging were assessed. In addition, we reviewed the medical literature for the association of ventriculomegaly/hydrocephalus (VM/HC) in JBTS. Only seven cases (from five families) were found with prenatal onset of VM/HC, diagnosed during the second trimester; three pregnancies were terminated, one was stillborn and three were born, of which one died within a week, and another died at the age of 6 years. Additional central nervous system findings included dysgenesis of the corpus callosum, delayed sulcation, polymicrogyria, and pachygyria. We found 16 publications describing 54 patients with JBTS and VM/HC: only five were diagnosed at birth and three were diagnosed prenatally. Hydrocephalus is extremely rare in JBTS. The recurrence of this association, reported in several publications in multiple family members, suggests that it might represent a new phenotypic subtype of JBTS possibly associated with specific genes or variants. Further genetic studies are needed to confirm this hypothesis. What this paper adds: The association of fetal hydrocephalus with Joubert‐Boltshauser syndrome (JBTS) is very rare but not a chance association.This association represents a new phenotypic subtype of JBTS possibly linked to specific genes or variants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Factors influencing drug toxicity

Author

Gupta, Rachna, primary, Rajpoot, Kuldeep, additional, Tekade, Muktika, additional, Sharma, Mukesh Chandra, additional, Safavi, Maliheh, additional, and Tekade, Rakesh Kumar, additional

Published
2022
Full Text
View/download PDF

27. List of contributors

Author

Arafat, Basel, primary, Asati, Saket, additional, Bagul, Swati, additional, Behera, Santosh Kumar, additional, Borisa, Pooja, additional, Chatterjee, Bappaditya, additional, Chaudhari, Sayali, additional, Christian, Jenee R., additional, Desai, Nimeet, additional, Deshpande, Mrudul, additional, Gandhi, Sanyam, additional, Gomte, Shyam Sudhakar, additional, Gour, Vishal, additional, Gupta, Deepak, additional, Gupta, Rachna, additional, Jhariya, Aditya Narayan, additional, Joshi, Megha, additional, Katare, Pratik, additional, Koppisetti, Hari Priya, additional, Koppisetti, HariPriya, additional, Kulkarni, Madhur, additional, Kumar, Manoj, additional, Lingayat, Isha, additional, Makwana, Vaishali, additional, Malviya, Neelesh, additional, Malviya, Sapna, additional, Manchikalapudi, Aparna Lakshmi, additional, Mishra, Ankit, additional, Mishra, Dinesh Kumar, additional, Mishra, Pranali, additional, Molugulu, Nagashekhara, additional, Muthuvijayan, Vignesh, additional, Nalla, Lakshmi Vineela, additional, Pande, Shreya, additional, Pandey, Vikas, additional, Parikh, Kinjal J., additional, Pawar, Bhakti, additional, Petwal, Aditi, additional, Pingale, Prashant, additional, Polaka, Suryanarayana, additional, Pramanik, Sheersha, additional, Pulugu, Priyanka, additional, Rajani, Chitra, additional, Raji, Sivaroopa, additional, Rajpoot, Kuldeep, additional, Rajput, Amarjitsing, additional, Safavi, Maliheh, additional, Salvi, Neelima, additional, Satvase, Rutuja, additional, Sengupta, Pinaki, additional, Sharma, Mukesh Chandra, additional, Shukla, Kajal, additional, Soni, Vandana, additional, Tambe, Vishakha, additional, Tekade, Muktika, additional, Tekade, Rakesh Kumar, additional, Tella, Jai Divya, additional, Tiwari, Akhilesh, additional, Tiwari, Rahul, additional, and Vasdev, Nupur, additional

Published
2022
Full Text
View/download PDF

29. Comprehensive post-mortem evaluation in Intrauterine deaths /still births in improving uptake of autopsy and future pregnancy outcomes

Author

Thakur, Seema, primary, Kadam, Khushboo, additional, Paliwal, Preeti, additional, Singh, Shubhnita, additional, Singh, Chanchal, additional, Gupta, Rachna, additional, Dagar, Savita, additional, Jain, Sudhir, additional, Sharma, Akshatha, additional, Saxena, Renu, additional, Saxena, Kamal, additional, Kohli, Sudha, additional, Thareja, Vandana, additional, Saxena, Rajni, additional, Caprihan, Renu, additional, Grover, Vimal, additional, Bhutani, Manorma, additional, Gupta, Anita, additional, Kumar, Neena, additional, Gupta, Vandana, additional, Mittal, Mamta, additional, Verma, Sunita, additional, Jain, Arpana, additional, Chakerverty, Jyoti, additional, Kapila, Mukta, additional, Mittal, Swati, additional, Kapoor, Sunita, additional, and Khurana, Deepa, additional

Published
2024
Full Text
View/download PDF

36. Neuroinvasion of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2): future risk of epilepsy.

Author

Kumar, Hemant and Gupta, Rachna

Subjects
*SARS-CoV-2, *EPILEPSY, *COVID-19, *NEUROLOGIC manifestations of general diseases, *CEREBROVASCULAR disease
Abstract

Central nervous system (CNS) infection is one of the important risk factors for epilepsy. COVID-19 pandemic, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has primarily been considered to involve respiratory system only, but it can also affect the CNS. A wide range of neurological manifestations have been reported in SARS-CoV-2 infected patients including seizures, status epilepticus, stroke, which are considered as important risk factors for the development of epilepsy. In post-mortem, brain tissue samples of COVID-19 patients have shown neuropathological changes and presence of SARS-CoV-2 RNA and viral proteins. In this review, mechanisms of SARS-CoV-2 neuroinvasion like neuronal retrograde trans-synaptic route and vascular route are described along with important neurological manifestations in COVID-19 patients such as seizures and cerebrovascular diseases, which have been found to be associated with the development of epilepsy. Hence, an increased risk of future burden of epilepsy in susceptible COVID-19 survivors has been proposed and preventive measures are suggested. The present review highlights about the possible association between neurological manifestations and future risk of epilepsy in COVID-19 patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers.

Author

Arockiaraj, Norman, Gupta, Rachna, Ahmad, Rafat, Halder, Sumita, and Bhatia, M. S.

Subjects
*COMBINATION drug therapy, *PATIENT safety, *SEROTONIN uptake inhibitors, *MIRTAZAPINE, *STATISTICAL sampling, *SCIENTIFIC observation, *SERTRALINE, *CLASSIFICATION of mental disorders, *RANDOMIZED controlled trials, *HAMILTON Depression Inventory, *LONGITUDINAL method, *DRUG efficacy, *COMPARATIVE studies, *MENTAL depression, *INTERLEUKINS, *TUMOR necrosis factors, *BIOMARKERS, *PHARMACODYNAMICS, *EVALUATION
Abstract

This study evaluated the effect of sertraline with desvenlafaxine and sertraline with mirtazapine on HAM-D score and inflammatory markers (IL-6 and TNF-α levels) in major depressive disorder. Patients (18–60 years) with MDD diagnosed by DSM-V criteria and HAM-D score 18 or more were included (n = 60). Group A patients (n = 30) received sertraline 50 mg/day and desvenlafaxine 50 mg/day. Group B patients (n = 30) received sertraline 50 mg/day and mirtazapine 30 mg/day. All patients were followed up for 8 weeks for the evaluation of clinical efficacy, safety, serum IL-6, and TNF-α levels. Our study showed a comparatively similar and statistically significant (p < 0.05) reduction in HAM-D score in both groups in the 4th and 8th week of the treatment. Both drug combinations significantly (p < 0.05) decreased serum IL-6 and TNF-α after 8 weeks of treatment. The present study suggests that the combination therapy (as treatment initiation) with sertraline and desvenlafaxine, and sertraline with mirtazapine is effective and well tolerated in MDD patients with moderate to severe depression, and their therapeutic efficacy is accompanied by decreased inflammatory markers (serum IL-6 and TNF-α). Recent evidence indicates that combination therapy of antidepressant drugs started as treatment initiation produces superior treatment outcomes in patients of MDD with moderate to severe depression. MDD is associated with increased inflammatory markers. Combination therapy of sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation is effective and well tolerated in MDD patients. The therapeutic efficacy of sertraline with desvenlafaxine and sertraline with mirtazapine is associated with a significant decrease in serum levels of IL-6 and TNF-α. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. List of contributors

Author

Alvarez-Puebla, Ramon A., primary, Ameta, Rakesh Kumar, additional, Anandan, Sambandam, additional, Ansari, Shahid Pervez, additional, Asiri, Abdullah M., additional, Babu, D. Prakash, additional, Banerjee, Prasun, additional, Chandra Babu Naidu, K., additional, Deepa, C., additional, Elakkiya, Rajasekaran, additional, Eswara Rao, P C.V.V., additional, Franco, Adolfo, additional, Guerrini, Luca, additional, Gupta, Rachna, additional, Gurusamy, Lakshmanan, additional, Herrera-Herrera, Antonio V., additional, Husain, Ahmad, additional, Janardan, S., additional, Khan, Anish, additional, Kumar, G. Ranjith, additional, Kumar, N. Suresh, additional, Kuppuswamy, N., additional, Maduraiveeran, Govindhan, additional, Malik, Parth, additional, Manjunatha, H., additional, Muthukrishnan, M., additional, Natarajan, Srinivasan, additional, Ni, Wei, additional, Noorjahaan, M., additional, Praveen, S., additional, Ramesh, M., additional, Ramesh, S., additional, Ramezanzadeh, Bahram, additional, Ramezanzadeh, Mohammad, additional, Rao, L. Vaikunta, additional, Ratnam, K. Venkata, additional, Ratnamala, A., additional, Reddy, G. Deepthi, additional, Reddy, K. Rama Krishna, additional, Rodríguez Delgado, Miguel Ángel, additional, Rodríguez-Ramos, Ruth, additional, Santana-Mayor, Álvaro, additional, Shariq, Mohd Urooj, additional, Sivarmakrishna, A., additional, Socas Rodríguez, Bárbara, additional, Srinivas, K., additional, Suresh Kumar, N., additional, Venkata Shiva Reddy, B., additional, Wu, Jerry J., additional, and Zorlu, Tolga, additional

Published
2021
Full Text
View/download PDF

49. Sugammadex versusNeostigmine for Reversal of Neuromuscular Blockade in Adults and Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Author

Chhabra, Ridhi, Gupta, Rachna, and Gupta, Lalit K.

Abstract

Background: Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and pediatric populations.Methods: PubMed and ScienceDirect were searched as the primary databases. Randomized controlled trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric patients have been included. The primary efficacy endpoint was the time from initiation of sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events have been reported as secondary outcomes.Results: A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95% CI [-16.88, -11.43], P< 0.01), as well as in children (mean difference = -26.36 min; 95% CI [- 40.16, -12.57], P< 0.01). Events of PONV have been found to be similar in both the groups in adults, but significantly lower in children treated with sugammadex,i.e., 7 out of 145 with sugammadex versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).Conclusion: Sugammadex is associated with a significantly shorter period of reversal from NMB in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex for NMB antagonism may offer a better option for pediatric patients.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results